Panama7/iStock Editorial via Getty Images
- Shares of Nurix Therapeutics (NASDAQ:NRIX) traded higher on Wednesday after the company announced a licensing agreement with Sanofi (NASDAQ:SNY) to advance a clinical program targeted at autoimmune diseases.
- The exclusive licensing deal covers a previously undisclosed Nurix (NASDAQ:NRIX) program